(186) Cost‑effectiveness evaluation of add‑on dapagliflozin for heart failure with reduced ejection fraction among patients without type 2 diabetes
Background: The addition of dapagliflozin to standard of care (SoC) has been shown to reduce hospitalization for heart failure and cardiovascular mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Objectives: We aimed to evaluate the cost-effectiveness of dapagliflozin added to SoC versus SoC in HFrEF and without type 2 diabetes (T2D) patients from the Qatari healthcare perspective.
Methods: A lifetime Markov model was constructed in 1,000 hypothetical HFrEF and without T2D patients using 3-month cycles over a 20-year horizon. The main outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year gained (QALY).
Results: The addition of dapagliflozin to SoC resulted in 0.05 incremental QALYs gained, yielding an ICER of QAR 53,204 (USD 14,616) per QALYs gained.
Conclusions: The addition of dapagliflozin to SoC is likely to be a cost-effective therapy for HFrEF and without T2D patients in Qatar.
